We can change the future of FSHD. Double your impact while matching funds last!

Reschedule to Thursday, December ber 11 | 1:00 PM ET
This FSHD University webinar will take a closer look at how gene therapy is being developed to target the root cause of FSHD. Our presenters will explain the science behind gene therapy, including how it works and what makes it a promising approach for treating FSHD. The session will also explore the use of adeno-associated virus (AAV) as a delivery method in gene therapy, and what factors patients should consider before joining a clinical trial—such as eligibility, safety, and long-term follow-up. Finally, Epicrispr will share updates and answer questions about their investigational FSHD therapy, EPI-321, currently in development.
Register Here